Media & Investors

Press Releases

Date Title Media
11/30/18
Summary ToggleCalithera Biosciences to Participate in the 2018 Citi Global Healthcare Conference
11/07/18
Summary ToggleCalithera Biosciences Reports Third Quarter 2018 Financial Results and Recent Highlights
10/31/18
Summary ToggleCalithera Biosciences to Report Third Quarter 2018 Financial Results on Wednesday, November 7, 2018
10/05/18
Summary ToggleCalithera Biosciences Highlights Breadth of Innovative Pipeline at R&D Day
10/05/18
Summary ToggleCalithera Biosciences Announces Clinical Trial Collaboration to Evaluate IBRANCE® (palbociclib) and talazoparib in Combination with CB-839
09/26/18
Summary ToggleCalithera Biosciences to Host R&D Day and Webcast on October 5, 2018
09/24/18
Summary ToggleCalithera Biosciences to Present at the 2018 Cantor Fitzgerald Global Healthcare Conference and the Leerink Partners Rare Disease & Oncology Roundtable
08/29/18
Summary ToggleCalithera Biosciences to Participate in the Citi 13th Annual Biotech Conference and the Wells Fargo Healthcare Conference
08/07/18
Summary ToggleCalithera Biosciences Reports Second Quarter 2018 Financial Results and Recent Highlights
08/01/18
Summary ToggleCalithera Biosciences to Report Second Quarter 2018 Financial Results on Tuesday, August 7, 2018
06/06/18
Summary ToggleCalithera to Present at the Jefferies and JMP Securities Healthcare Conferences in June
06/04/18
Summary ToggleResults from Phase 1 Study of CB-839 in Combination with Capecitabine in Advanced Solid Tumors to be Presented at the 2018 American Society of Clinical Oncology (ASCO)
05/10/18
Summary ToggleCalithera Biosciences Reports First Quarter 2018 Financial Results and Recent Highlights
04/25/18
Summary ToggleCalithera Biosciences Announces CB-839 Abstracts Accepted for Presentation at ASCO 2018
04/18/18
Summary ToggleCalithera Biosciences Announces FDA Fast Track Designation Granted to CB-839 in Combination with Cabozantinib for Treatment of Patients with Advanced Renal Cell Carcinoma
04/13/18
Summary ToggleCalithera Biosciences to Present New Preclinical Data for CB-839 at AACR Annual Meeting 2018
03/23/18
Summary ToggleCalithera to Present at Needham & Company 17th Annual Healthcare Conference
03/08/18
Summary ToggleCalithera Biosciences Reports Fourth Quarter 2017 Financial Results and Recent Highlights
03/06/18
Summary ToggleCalithera to Present at Cowen & Company 38th Annual Health Care Conference
03/02/18
Summary ToggleCalithera Biosciences to Report Fourth Quarter 2017 Financial Results on Thursday, March 8, 2018
02/09/18
Summary ToggleCalithera to Participate in Leerink Partners 7th Annual Global Healthcare Conference
02/05/18
Summary ToggleResults from Phase I Study of CB-839 in Combination with Everolimus or Cabozantinib in Patients with Renal Cell Carcinoma to be Presented at the 2018 American Society of Clinical Oncology Genitourinary Cancer Symposium
12/05/17
Summary ToggleUpdated Results from Phase I Study of CB-839 in Combination with Paclitaxel in Patients with Triple Negative Breast Cancer to be Presented at the 2017 San Antonio Breast Cancer Symposium
11/07/17
Summary ToggleInitial Results from Phase 2 Study of CB-839 in Combination with Opdivo® (nivolumab) to be Presented at the Society for Immunotherapy of Cancer Meeting
11/02/17
Summary ToggleCalithera Biosciences Reports Third Quarter 2017 Financial Results and Recent Highlights
10/19/17
Summary ToggleCalithera Announces First Patient Treated in Phase 1 Cohort of INCB01158 dosed in Combination with Keytruda
10/03/17
Summary ToggleCalithera Biosciences Announces Appointment of Sumita Ray as General Counsel
09/21/17
Summary ToggleCalithera Biosciences Appoints Blake Wise to Board of Directors
09/20/17
Summary ToggleCalithera Biosciences to Present at the 2017 Cantor Fitzgerald Global Healthcare Conference and the Leerink Partners Immuno-Oncology Roundtable
09/19/17
Summary ToggleCalithera Biosciences Announces CB-839 in Combination with Nivolumab Phase 1/2 Data Accepted for Oral Presentation at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting
08/30/17
Summary ToggleCalithera Biosciences to Participate in the Citi 12th Annual Biotech Conference and the Wells Fargo Healthcare Conference
08/08/17
Summary ToggleCalithera Biosciences Reports Second Quarter 2017 Financial Results and Recent Highlights
08/07/17
Summary ToggleCalithera Biosciences Initiates a Randomized Phase 2 Combination Trial of CB-839 in Patients with Renal Cell Carcinoma
08/02/17
Summary ToggleCalithera Biosciences to Report Second Quarter 2017 Financial Results on Tuesday, August 8, 2017
06/14/17
Summary ToggleCalithera Biosciences to Participate in the JMP Securities 2017 Life Sciences Conference
06/07/17
Summary ToggleCalithera Biosciences Announces FDA Fast Track Designation Granted to CB-839 for Treatment of Patients with Renal Cell Carcinoma
06/05/17
Summary ToggleCB-1158 (INCB01158) Phase I Solid Tumor Data Presented at the American Society of Clinical Oncology Annual Meeting
05/10/17
Summary ToggleBristol-Myers Squibb and Calithera Biosciences Expand Collaboration Evaluating Opdivo (nivolumab) in Combination with CB-839 into Non-Small Cell Lung Cancer and Melanoma
05/09/17
Summary ToggleCalithera Biosciences Reports First Quarter 2017 Financial Results and Recent Highlights
05/03/17
Summary ToggleCalithera Biosciences to Report First Quarter 2017 Financial Results on Tuesday, May 9, 2017
04/20/17
Summary ToggleCB-1158 Phase I Data Accepted for an Oral Presentation at the ASCO Annual Meeting
03/29/17
Summary ToggleCalithera Biosciences to Present at the 16th Annual Needham Health Care Conference
03/28/17
Summary ToggleCalithera to Receive $12 Million Milestone Payment From Incyte for Achievement of Pharmacokinetic and Pharmacodynamic Goals in Phase 1 Study
03/27/17
Summary ToggleCalithera Biosciences, Inc. Announces Closing of Public Offering and Exercise in Full of Option to Purchase Additional Shares
03/22/17
Summary ToggleCalithera Biosciences, Inc. Prices Public Offering of 6,830,000 shares of Common Stock
03/20/17
Summary ToggleCalithera Biosciences, Inc. Announces Commencement of Underwritten Public Offering of Common Stock
03/16/17
Summary ToggleCalithera Biosciences Reports Fourth Quarter and Full Year 2016 Financial Results and Recent Highlights
03/10/17
Summary ToggleCalithera Biosciences to Report Fourth Quarter and Year-End 2016 Financial Results on Thursday, March 16, 2017
03/01/17
Summary ToggleCalithera Biosciences to Present at Cowen and Company 37th Annual Health Care Conference
02/09/17
Summary ToggleCalithera Biosciences to Present at the BIO CEO & Investor and Leerink Global Healthcare Conferences in February
01/30/17
Summary ToggleIncyte and Calithera Biosciences Announce Global Collaboration to Develop and Commercialize CB-1158, a First-in-class, Small Molecule Arginase Inhibitor
12/21/16
Summary ToggleBristol-Myers Squibb and Calithera Biosciences Announce Clinical Collaboration to Evaluate Opdivo (nivolumab) in Combination with CB-839 in Clear Cell Renal Cell Carcinoma
12/12/16
Summary ToggleCalithera Biosciences Announces Key Management Changes
12/09/16
Summary ToggleCalithera Biosciences to Host Conference Call and Webcast to Review Data Presented at the San Antonio Breast Cancer Symposium and EORTC-NCI-AACR Symposium
12/06/16
Summary ToggleCalithera Biosciences Reports CB-839 Phase I Triple Negative Breast Cancer Combination Data at the 2016 San Antonio Breast Cancer Symposium
12/02/16
Summary ToggleCalithera Biosciences Announces CB-839 Preclinical Data Selected for Presentation at the 58th American Society of Hematology Annual Meeting
11/29/16
Summary ToggleCalithera Biosciences Reports CB-839 Phase I Renal Cell Carcinoma Combination Data at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
11/11/16
Summary ToggleCalithera Biosciences Announces Four Abstracts Selected for Presentation at the Society for Immunotherapy of Cancer (SITC) 2016 Annual Meeting
11/09/16
Summary ToggleCalithera Biosciences Reports Third Quarter 2016 Financial Results and Recent Highlights, and Raises Year-end Cash Guidance
11/02/16
Summary ToggleCalithera Biosciences to Report Third Quarter 2016 Financial Results on Wednesday, November 9, 2016
09/22/16
Summary ToggleCalithera Biosciences to Present at the Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology Roundtable
09/15/16
Summary ToggleCalithera Announces First Patient Dosed in a Phase I Study of CB-1158, the First-in-Class Inhibitor of the Immuno-Oncology Target Arginase
09/07/16
Summary ToggleCalithera Biosciences Announces CB-839 Clinical Data Selected for Oral Presentation at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
08/31/16
Summary ToggleCalithera Biosciences to Present at Two Healthcare Conferences in September
08/10/16
Summary ToggleCalithera Biosciences Appoints Suzy Jones to Board of Directors
08/09/16
Summary ToggleCalithera Biosciences Reports Second Quarter 2016 Financial Results and Recent Highlights
08/04/16
Summary ToggleCalithera Announces Enrollment of First Patient in CB-839 in Combination with Checkpoint Modulator
08/02/16
Summary ToggleCalithera Biosciences to Report Second Quarter 2016 Financial Results on Tuesday, August 9, 2016
07/25/16
Summary ToggleCalithera Biosciences Announces FDA Acceptance of Investigational New Drug Application for CB-1158, a Novel Arginase Inhibitor Targeting an Immune Metabolic Checkpoint
06/06/16
Summary ToggleCalithera Biosciences Reports CB-839 Phase I Solid Tumor Combination Data at the American Society of Clinical Oncology Annual Meeting
05/10/16
Summary ToggleCalithera Biosciences Reports First Quarter 2016 Financial Results and Recent Highlights
05/03/16
Summary ToggleCalithera Biosciences to Report First Quarter 2016 Financial Results on Tuesday, May 10, 2016
04/21/16
Summary ToggleCalithera Biosciences Announces Clinical Data Presentations at ASCO 2016
04/18/16
Summary ToggleCalithera Biosciences Announces Four Preclinical Presentations at the American Association for Cancer Research Annual Meeting 2016
04/08/16
Summary ToggleCalithera Biosciences to Present at the 15th Annual Needham Healthcare Conference
03/15/16
Summary ToggleCalithera Biosciences Reports Fourth Quarter and Full Year 2015 Financial Results and Recent Highlights
03/08/16
Summary ToggleCalithera Biosciences to Report Fourth Quarter and Year-End 2015 Financial Results on Tuesday, March 15, 2016
03/01/16
Summary ToggleCalithera Biosciences to Present at Cowen and Company 36th Annual Health Care Conference
02/02/16
Summary ToggleCalithera Biosciences to Present at the BIO CEO & Investor and Leerink Global Healthcare Conferences in February
01/22/16
Summary ToggleCalithera Biosciences Announces Abstract Selected for Oral Presentation at the 2016 Keystone Symposia
12/06/15
Summary ToggleCalithera Biosciences Reports Phase I Data for CB-839 in Patients With Hematological Malignancies at the 57th American Society of Hematology Annual Meeting
11/16/15
Summary ToggleCalithera Presents Preclinical Study Findings for CB-839 at the 2015 Novel Cancer Therapeutics Summit
11/09/15
Summary ToggleCalithera Biosciences Reports Third Quarter 2015 Financial Results and Recent Highlights
11/08/15
Summary ToggleCalithera to Present New Phase 1 Solid Tumor Dose Expansion Data of CB-839 at the 2015 AACR-NCI-EORTC International Conference
11/06/15
Summary ToggleCalithera Presents Preclinical Study Findings for CB-1158 at the 2015 AACR-NCI-EORTC International Conference
11/05/15
Summary ToggleCalithera Announces Multiple Abstracts Selected for Presentation at the 57th American Society of Hematology Annual Meeting
10/30/15
Summary ToggleCalithera Biosciences to Report Third Quarter 2015 Financial Results on Monday, November 9, 2015
10/26/15
Summary ToggleCalithera Announces Multiple Abstracts Selected for Presentation at the 2015 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
09/30/15
Summary ToggleCalithera Biosciences Appoints Sunil Agarwal, M.D., to Its Board of Directors
09/23/15
Summary ToggleCalithera Biosciences to Present at the Leerink Partners Inaugural Immuno-Oncology Roundtable Conference
09/02/15
Summary ToggleCalithera Biosciences to Participate in Two Healthcare Conferences in September
08/10/15
Summary ToggleCalithera Biosciences Reports Second Quarter 2015 Financial Results and Recent Highlights
08/05/15
Summary ToggleCalithera Biosciences to Report Second Quarter 2015 Financial Results on Monday, August 10, 2015
06/23/15
Summary ToggleCalithera Biosciences Selects Immuno-Oncology Clinical Candidate CB-1158, an Oral Arginase Inhibitor for the Treatment of Cancer
06/16/15
Summary ToggleCalithera Biosciences to Present at the JMP Securities Life Sciences Conference 2015
06/11/15
Summary ToggleCalithera Biosciences Reports Phase I Data for CB-839 in Patients With Acute Leukemias at the 20th Congress of the European Hematology Association
05/30/15
Summary ToggleCalithera Reports Phase I Data for CB-839 in Patients with Solid Tumors at the 2015 American Society of Clinical Oncology
05/21/15
Summary ToggleCalithera Reports Initial Phase I Data for CB-839 in Patients with Acute Leukemias
05/07/15
Summary ToggleCalithera Biosciences Reports First Quarter 2015 Financial Results and Recent Highlights
05/07/15
Summary ToggleCalithera Biosciences to Present at the Bank of America Merrill Lynch 2015 Healthcare Conference - Revised Date of Presentation
05/06/15
Summary ToggleCalithera Biosciences to Present at the Bank of America Merrill Lynch 2015 Healthcare Conference
04/30/15
Summary ToggleCalithera Biosciences to Report First Quarter 2015 Financial Results on Thursday, May 7, 2015
04/22/15
Summary ToggleCalithera Biosciences Announces Clinical Data Presentation at ASCO 2015
04/21/15
Summary ToggleCalithera Biosciences Highlights Results From Six Preclinical Abstracts at the American Association for Cancer Research Annual Meeting 2015
04/09/15
Summary ToggleCalithera Biosciences to Present at the 14th Annual Needham Healthcare Conference
03/26/15
Summary ToggleCalithera Biosciences Reports Fourth Quarter and Full Year 2014 Financial Results and Recent Highlights
03/20/15
Summary ToggleCalithera Biosciences to Report Fourth Quarter and Year-End 2014 Financial Results on Thursday, March 26, 2015
03/18/15
Summary ToggleCalithera Biosciences Announces Five Data Presentations at the American Association for Cancer Research Annual Meeting 2015
03/05/15
Summary ToggleCalithera Biosciences Gains Exclusive, Worldwide License to TransTech Pharma's Hexokinase II Inhibitor Program
02/03/15
Summary ToggleCalithera Biosciences to Present at the BIO CEO & Investor and Leerink Global Healthcare Conferences in February
01/30/15
Summary ToggleCalithera Biosciences Appoints Keith Orford, M.D., Ph.D. to Vice President of Clinical Development
12/10/14
Summary ToggleCalithera Presents Novel Pharmacodynamic Assay Data Confirming Glutaminase Inhibition in Tumor Biopsy Samples From Patients Treated With CB-839
12/09/14
Summary ToggleCalithera Biosciences Gains Exclusive, Worldwide License to Mars Symbioscience's Arginase Inhibitors
12/08/14
Summary ToggleCalithera Presents Preclinical Study Findings for CB-839 at the 56th American Society of Hematology Annual Meeting
12/02/14
Summary ToggleCalithera Biosciences Appoints H. Ward Wolff to Board of Directors
11/14/14
Summary ToggleCalithera Reports Financial Results for the Fiscal Quarter Ended September 30, 2014
11/06/14
Summary ToggleCalithera Announces Multiple Abstracts Selected for Presentation at the 56th American Society of Hematology Annual Meeting
10/02/14
Summary ToggleCalithera Biosciences, Inc. Announces Pricing of Initial Public Offering
04/08/14
Summary ToggleCalithera Biosciences Presents Pharmacodynamic Data on CB-839 at the 2014 American Association for Cancer Research Annual Meeting
04/01/14
Summary ToggleCalitheraBiosciences to Present Data on CB-839 at the American Association for Cancer Research Annual Meeting 2014
03/25/14
Summary ToggleCalithera Biosciences Appoints William D. Waddill Chief Financial Officer
03/18/14
Summary ToggleCalithera Biosciences Presents Preclinical Data for CB-839Activity and Glutaminase Inhibition in Solid and Hematologic Tumors
02/24/14
Summary ToggleCalithera Biosciences Initiates ThreePhase 1 Trials with First-in-Class Glutaminase Inhibitor CB-839 in Patients with Advanced Solid and Hematological Cancers
12/12/13
Summary ToggleCalithera Biosciences Presents Data for CB-839 in TripleNegative Breast Cancer Models at the 2013 San Antonio Breast Cancer Symposium
12/10/13
Summary ToggleCalithera Biosciences Presents Preclinical Data for CB-839 at the 55th American Society ofHematology Annual Meeting
11/26/13
Summary ToggleCalithera Biosciences to Present Data at the 55th American Society for Hematology Annual Meeting and the 2013 San Antonio Breast Cancer Symposium
10/29/13
Summary ToggleCalithera Biosciences Secures $35 Million in Series D Financing
07/08/10
Summary ToggleCalithera Biosciences closes $40 Million in Series A Financing